Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Halozyme and decreased the price target to $79.00 from $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors including Halozyme’s strong royalty revenue performance and disciplined cost management, which are expected to drive earnings per share (EPS) above expectations for the remainder of 2025. The company has already raised its financial guidance twice this year, reflecting confidence in its revenue streams, particularly in royalties.
However, Sean Laaman acknowledges potential risks, such as the uncertainties surrounding the CMS final guidance on drug price negotiations and the proposed acquisition of Elektrofi. While these factors could pose long-term challenges, the current financial outlook and strategic initiatives provide a solid foundation for growth, justifying the Buy rating.
In another report released on October 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $90.00 price target.